What is it about?
Leishmaniasis current treatment is toxic, long, and limited due to high parasite resistance. Microbial metabolites and their structural analogues with enormous scaffold diversity and structural complexity play key role in drug discovery. Thirty-nine research articles published between 1999 and 2021 in the scientific database (PubMed, Science Direct) describing microbes and their metabolites with activity against leishmanial parasites.
Featured Image
Photo by National Cancer Institute on Unsplash
Why is it important?
Leishmaniasis and new perspectives for treatment.
Perspectives
Microbial metabolites and their structural analogues with enormous scaffold diversity and structural complexity play a key role in drug discovery.
Dr. Jorge A. López
Read the Original
This page is a summary of: Anti-leishmanial compounds from microbial metabolites: a promising source, Applied Microbiology and Biotechnology, October 2021, Springer Science + Business Media,
DOI: 10.1007/s00253-021-11610-6.
You can read the full text:
Resources
Contributors
The following have contributed to this page
